Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

Clinical trial NCT00901147 · COMPLETED

Trial details

NCT number: NCT00901147
Sponsor: Singapore General Hospital
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Peripheral T-cell Lymphoma (Not Otherwise Specified)Angioimmunoblastic T-cell Lymphoma Extranodal NK/T-cell Lymphoma Nasal Type Enteropathy- Type T-cell Lymphoma Hepatosplenic T-cell Lymphoma Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant

Start date: 2009-11-01
Primary completion: 2014-01-01
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.